• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by ENvue Medical Inc.

    2/6/26 4:54:54 PM ET
    $FEED
    Industrial Specialties
    Health Care
    Get the next $FEED alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    ENvue Medical, Inc.

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    63008J884

    (CUSIP Number)


    01/30/2026

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    63008J884


    1Names of Reporting Persons

    BANK OF AMERICA CORP /DE/
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    234,235.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    234,235.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    234,235.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    21.5 %
    12Type of Reporting Person (See Instructions)

    HC

    Comment for Type of Reporting Person:  The beneficial ownership calculation relies on the 1,088,192 outstanding shares disclosed in the Form 424B3 - Prospectus by the issuer on December 18, 2025, which reports share totals as of December 5, 2025. The prospectus pertains to the resale, from time to time, by selling stockholders of up to 7,962,279 shares of common stock. While not yet finalized, the issuance of additional shares could materially increase the number of outstanding common shares and result in substantial dilution to existing stockholders.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    ENvue Medical, Inc.
    (b)Address of issuer's principal executive offices:

    969 PRUITT AVE,, TYLER, TEXAS, 77569.
    Item 2. 
    (a)Name of person filing:

    BANK OF AMERICA CORP /DE/
    (b)Address or principal business office or, if none, residence:

    100 N TRYON ST CHARLOTTE, NC 28255
    (c)Citizenship:

    Delaware
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    63008J884
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    234,235.00
    (b)Percent of class:

    21.5%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0.00

     (ii) Shared power to vote or to direct the vote:

    234,235.00

     (iii) Sole power to dispose or to direct the disposition of:

    0.00

     (iv) Shared power to dispose or to direct the disposition of:

    234,235.00

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Not Applicable
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.


    This statement on Schedule 13G is being filed by Bank of America Corporation on behalf of itself and its wholly owned subsidiaries BofA Securities, Inc., a broker dealer registered under section 15 of the Act (15 U.S.C. 78o); and Bank of America N.A., a bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    BANK OF AMERICA CORP /DE/
     
    Signature:/s/ Andres Ortiz
    Name/Title:Authorized Signatory
    Date:02/06/2026
    Get the next $FEED alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $FEED

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $FEED
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by ENvue Medical Inc.

    SCHEDULE 13G - ENvue Medical, Inc. (0001326706) (Subject)

    2/6/26 4:54:54 PM ET
    $FEED
    Industrial Specialties
    Health Care

    SEC Form 8-K filed by ENvue Medical Inc.

    8-K - ENvue Medical, Inc. (0001326706) (Filer)

    2/6/26 4:05:35 PM ET
    $FEED
    Industrial Specialties
    Health Care

    ENvue Medical Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

    8-K - ENvue Medical, Inc. (0001326706) (Filer)

    1/30/26 4:30:46 PM ET
    $FEED
    Industrial Specialties
    Health Care

    $FEED
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: New insider Bank Of America Corp /De/ claimed ownership of 234,056 shares (SEC Form 3)

    3/A - ENvue Medical, Inc. (0001326706) (Issuer)

    2/5/26 8:48:13 AM ET
    $FEED
    Industrial Specialties
    Health Care

    Large owner Bank Of America Corp /De/ sold $8,906 worth of shares (2,918 units at $3.05) (SEC Form 4)

    4 - ENvue Medical, Inc. (0001326706) (Issuer)

    2/4/26 9:03:17 PM ET
    $FEED
    Industrial Specialties
    Health Care

    New insider Bank Of America Corp /De/ claimed ownership of 234,056 shares (SEC Form 3)

    3 - ENvue Medical, Inc. (0001326706) (Issuer)

    2/4/26 3:21:05 PM ET
    $FEED
    Industrial Specialties
    Health Care

    $FEED
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ENvue Medical Signs Strategic Partnership Agreement with U-Deliver for U.S. Distribution of Over-the-Counter Reusable ENFit Syringe Line

    TYLER, Texas, Jan. 28, 2026 (GLOBE NEWSWIRE) -- ENvue Medical, Inc. (NASDAQ:FEED) (NASDAQ:NAOV) ("ENvue," "ENvue Medical" or the "Company"), a medical technology company specializing in the advancement of intelligent, non-invasive solutions for enteral care across clinical and home care settings, today announced the signing of a distribution agreement with U-Deliver to distribute ENvue's recently launched over-the-counter reusable ENFit Syringes product line nationwide through non-acute care channels. "We believe that our partnership with U-Deliver is an important step in scaling ENvue's over-the-counter ENFit syringe line and strengthening our presence in the non-acute enteral care marke

    1/28/26 9:00:00 AM ET
    $FEED
    $NAOV
    Industrial Specialties
    Health Care

    ENvue Medical Appoints Industry Veteran Marc Waldman as Vice President, Commercial

    TYLER, Texas, Jan. 21, 2026 (GLOBE NEWSWIRE) -- ENvue Medical, Inc. (NASDAQ:FEED) (NASDAQ:NAOV) ("ENvue," "ENvue Medical" or the "Company"), a medical technology company specializing in the advancement of intelligent, non-invasive solutions for enteral care across clinical and home care settings, today announced the appointment of Marc Waldman as Vice President, Commercial. In this role, Mr. Waldman will lead ENvue's U.S. commercialization strategy, with a focus on expanding its existing presence in 38 hospitals and accelerating revenue across the Company's enteral platform. "Marc is a highly accomplished sales leader with extensive GPO and IDN expertise and long-standing relationships th

    1/21/26 8:30:00 AM ET
    $FEED
    $NAOV
    Industrial Specialties
    Health Care

    ENvue Medical Launches Over-the-Counter Reusable ENFit Syringes to Support Feeding and Medication Delivery without a Prescription

    TYLER, Texas, Jan. 14, 2026 (GLOBE NEWSWIRE) -- ENvue Medical, Inc. (NASDAQ:FEED) (NASDAQ:NAOV) ("ENvue," "ENvue Medical" or the "Company"), a medical technology company specializing in the advancement of intelligent, non-invasive solutions for enteral care across clinical and home care settings, today announced the launch of a line of over-the-counter ENFit Syringes designed to meet both feeding and medication delivery clinical needs. "As care continues to shift beyond the hospital setting, providers and caregivers need reliable, high-quality solutions that support patients throughout the entire care journey," said Doron Besser, MD, CEO of ENvue Medical. "With the launch of our over-the-

    1/14/26 8:30:00 AM ET
    $FEED
    $NAOV
    Industrial Specialties
    Health Care

    $FEED
    Leadership Updates

    Live Leadership Updates

    View All

    ENvue Medical Appoints Industry Veteran Marc Waldman as Vice President, Commercial

    TYLER, Texas, Jan. 21, 2026 (GLOBE NEWSWIRE) -- ENvue Medical, Inc. (NASDAQ:FEED) (NASDAQ:NAOV) ("ENvue," "ENvue Medical" or the "Company"), a medical technology company specializing in the advancement of intelligent, non-invasive solutions for enteral care across clinical and home care settings, today announced the appointment of Marc Waldman as Vice President, Commercial. In this role, Mr. Waldman will lead ENvue's U.S. commercialization strategy, with a focus on expanding its existing presence in 38 hospitals and accelerating revenue across the Company's enteral platform. "Marc is a highly accomplished sales leader with extensive GPO and IDN expertise and long-standing relationships th

    1/21/26 8:30:00 AM ET
    $FEED
    $NAOV
    Industrial Specialties
    Health Care

    ENvue Medical Appoints Veteran Healthcare-Industry Executive, David Johnson, as Chairman

    ENvue Medical, Inc. (NASDAQ:FEED) ("ENvue" or the "Company"), a medical technology company specializing in non-invasive therapeutic systems, today announced the appointment of David Johnson as Chairman of the Board. Mr. Johnson will work alongside CEO, Doron Besser, and the existing leadership team. David Johnson, newly appointed Chairman of ENvue, stated, "We believe ENvue is at the forefront of advanced feeding-tube placement technology, which has been validated in the market and extensively used in the clinic across 38 hospitals in the US. In my opinion, the Company's unique feeding tube placement system that utilizes advanced methods of navigation, integrated sensors and body mapping h

    12/15/25 9:00:00 AM ET
    $ENVB
    $FEED
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Industrial Specialties